Radiopharm Theranostics (ASX:RAD)

Radiopharm Theranostics: Developing Innovative Radiopharmaceuticals for a Highly Underserved Oncology Sector


Radiopharm Theranostics (ASX:RAD) is a biopharmaceutical company that develops radiopharmaceutical products for diagnostic and therapeutic applications. With four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb), Radiopharm aims to commercialize its pipeline for possible licensing and distribution agreements seeking to develop for the diagnosis and treatment of certain cancers.

Radiopharm Theranostics represents a promising investment opportunity in the rapidly growing field of radiopharmaceuticals, leveraging its innovative technology platform and diverse clinical pipeline.

Radiopharm Theranostics imaging process

Radiopharm’s clinical stage development in the pipeline include:

  1. PD-L1 (non-small cell lung cancer indication) - currently in phase 1 in Australia;
  2. HER2 (breast/gastric cancer indication) - will begin phase 1 trials this year;
  3. Integrin VB6 (pancreatic cancer indication) - now in Phase I imaging in pancreatic cancer.
  4. Fatty Acid Synthase (brain METS indication) - preclinical has been completed and with IND approval for Phase IIb Imaging

Company Highlights

  • Radiopharm Theranostics is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology.
  • Radiopharm has four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb) – with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.
  • The company has received clearance from the US Food and Drug Administration for an investigational new drug application with two INDs (one for RAD 301 and one for RAD 101). Phase 1 for RAD 301 and for RAD 204 is in progress.
  • The company aims to commercialize its pipeline for possible licensing and distribution agreements and has secured four platform technologies, which it is seeking to develop for the diagnosis and treatment of certain cancers.

This Radiopharm Theranostics profile is part of a paid investor education campaign.*

Click here to connect with Radiopharm Theranostics (ASX:RAD) to receive an Investor Presentation

RAD:AU
Radiopharm Theranostics

Radiopharm Theranostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Radiopharm Theranostics

Radiopharm Theranostics


Keep reading...Show less
Radiopharm Theranostics (ASX:RAD)

Radiopharm Theranostics ‘Extends Runway’ to Key Milestones with AU$70M Investments: Report

Description

The AU$7.5 million strategic investment from Lanthues Holdings signals a strong endorsement of Radiopharm Theranostics’ (ASX:RAD) technology, extending the company's runway to key milestones, according to a new report from Diamond Equity Research.

Keep reading...Show less

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday Sept. 5, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, and Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Appendix 4E and Preliminary Final Report - For the Year Ended 30 June 2024

BPH Global Limited (ASX: BP8) (“BP8” or the “Company” or the “Group”) has released its Appendix 4E Preliminary Final Report.


Keep reading...Show less
Hydralyte

H1 FY24 Half Year Report and Appendix 4D: 29% Reduction in Net Cash Used in Operating Activities alongside Stable Revenue

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”) is pleased to provide the following update on the six-month period ended 30 June 2024 (the “half year” or “H1 FY2024”) and the Company’s Appendix 4D.

Keep reading...Show less
Lab worker putting samples on microscope.

Best-performing Small-cap Biotech Stocks on the ASX in 2024

The global biotechnology sector is on track to become a multi-trillion dollar industry.

Worldwide, the biotech space is worth an estimated US$1.76 trillion this year, according to Grand View Research. That value is expected to grow at a compound annual growth rate of 13.96 percent through 2030 to become a US$3.88 trillion market.

The major factors driving this growth are a strong clinical pipeline of precision medicine and regenerative technologies, as well as a rising demand for treatments for chronic diseases such as cancer, diabetes and neurological disorders.

Australia's biotech market is growing as well. In 2024, IBISWorld projects that the sector will see revenue of AU$10.8 billion.

Keep reading...Show less

AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22 nd Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday Sept. 4, 2024. Robert A. Bradway chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×